HCV enters the twenty-first century

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• High prevalence of co-infection between HIV and HCV globally.
• Hepatitis C virus-associated liver disease is a leading cause of mortality in HIV-infected individuals due to increased survival rates.
• Emerging transmission routes of HCV in specific populations, including HIV-infected men who have sex with men.

Purpose of the Study:

• To highlight the challenges in managing hepatitis C virus (HCV) coinfection in human immunodeficiency virus (HIV)-infected patients.
• To discuss the limitations of current HCV therapies in coinfected individuals.
• To identify key areas for future research in optimizing HCV treatment strategies for coinfected patients.

Main Methods:

• Review of current literature on HIV/HCV coinfection.
• Analysis of treatment guidelines and approved therapies for HCV.
• Discussion of epidemiological trends and transmission dynamics.

Main Results:

• Current direct-acting antiviral agents are effective but optimal combination, duration, and timing for coinfected patients remain undetermined.
• Telaprevir and boceprevir, while effective in monoinfection, are not approved for coinfected individuals.
• HCV treatment in coinfected patients presents unique challenges compared to HCV monoinfection.

Conclusions:

• Effective management of HCV in HIV-coinfected individuals requires further research to determine optimal treatment strategies.
• Addressing treatment complexities is crucial to reduce HCV-associated morbidity and mortality in this vulnerable population.
• The development of tailored therapeutic approaches is essential for improving long-term outcomes in coinfected patients.